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ABSTRACT
Umbilical cord blood (CB) from the early gestational human fetus is recognized as a rich source of hematopoi-
etic stem cells. To examine the value of fetal CB for gene therapy of inborn immunohematopoietic disorders,
we tested the feasibility of genetic modification of CD34 1 cells from CB at weeks 24 to 34 of pregnancy, us-
ing lentiviral vector-mediated transfer of the green fluorescent protein (GFP) gene. The transduction rate of
CD34 1 cells was 42 6 9%, resulting in GFP expression in 23 6 4% of colonies derived from colony-forming
units (CFUs) and 11 6 1% from primitive long-term culture-initiating cells (LTC-ICs). Cell cycle analysis
demonstrated transduction and GFP expression in cells in the G0 phase, which contains immature hematopoi-
etic progenitors. Transduced fetal CD34 1 cells could be expanded 1000-fold in long-term cultures supple-
mented with megakaryocyte growth and development factor along with Flt-3 ligand. At week 10, expression
of GFP was observed in 40.5 6 11.7% of CFU-derived colonies. While prestimulation of CD34 1 cells with cy-
tokines prior to transduction increased the efficiency of GFP transfer 2- to 3-fold, long-term maintenance of
GFP-expressing CFUs occurred only in the absence of prestimulation. The GFP gene was found integrated
into the genomic DNA of 35% of LTC-IC-derived colonies initiated at week 10, but GFP expression was not
detectable, suggesting downregulation of transgene activity during the extended culture period. These results
indicate that human fetal CB progenitors are amenable to genetic modification by lentiviral vectors and may
serve as a target for gene therapy of hematopoietic disorders by prenatal autologous transplantation.
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OVERVIEW SUMMARY
Although hematopoietic stem cells in preterm umbilical CB
are considered as targets for gene therapy of congenital dis-
eases in utero, gene transfer to these cells has not been at-
tempted. We used HIV-derived lentiviral vectors for GFP
gene transfer to human CD34 1 CB progenitors from weeks
24–34 of pregnancy. Transduction efficiency was 42 6 9%,
resulting in GFP expression in 23 6 4 and 11 6 1% of CFU-
and primitive LTC-IC-derived colonies, respectively. When
transduced fetal CD34 1 cells were expanded about 1000-
fold in cytokine-supplemented cultures for 10 weeks, ex-
pression of GFP was maintained in 40.5 6 11.7% of CFUs
and the GFP gene was found integrated into the DNA of
35% of LTC-ICs. GFP transfer efficiency was increased by
cytokine prestimulation preceding transduction of CD34 1
cells, but long-term maintenance of transgene expression
was superior in the absence of prestimulation. These results
provide evidence that preterm CB can be targeted for gene
transfer by lentiviral vectors.
INTRODUCTION
GENETIC MODIFICATION of hematopoietic stem cells is apromising approach for the treatment of inherited disor-
ders of the hematopoietic system, provided the relevant gene
can be stably expressed in cells with the capacity to self-renew
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and differentiate to the affected hematopoietic lineages. Lentivi-
ral vectors, based on the human immunodeficiency virus type
1 (HIV-1), have been developed and shown to be efficient for
the delivery and expression of genes in nondividing cells (Nal-
dini et al., 1996; Zufferey et al., 1997). For transduction of qui-
escent hematopoietic progenitors, these vectors may offer a sig-
nificant advantage over murine leukemia virus-derived vectors,
since they do not require mitotic cell divisions for stable inte-
gration into the host genome (Roe et al., 1993; Uchida et al.,
1998). The value of lentiviral vectors for gene delivery to bone
marrow-repopulating stem cells was demonstrated by sustained
transgene expression in recipient nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice transplanted
with transduced human CD341 progenitors (Miyoshi et al.,
1999).
Umbilical cord blood (CB) is an established source of
hematopoietic stem cells for allogeneic transplantation (Gluck-
man et al., 1997; Rubinstein et al., 1998). Moreover, autolo-
gous CB has been used for gene therapy in children with adeno-
sine deaminase deficiency (Kohn et al., 1995, 1998). With
advances in prenatal diagnosis, congenital defects can now be
identified in the first trimester of pregnancy, calling for the ear-
liest possible therapeutic intervention to prevent the manifesta-
tion of disease (Holzgreve, 1997). This could be achieved by
stem cell transplantation in utero before the development of any
tissue damage (Flake and Zanjani, 1999; Schneider and
Coutelle, 1999). Allogeneic transplantation has been success-
ful in fetuses with congenital immunodeficiency syndromes
profiting from a selective survival advantage of genetically cor-
rected lymphoid progenitors (Touraine et al., 1989, 1992; Flake
et al., 1996; Wengler et al., 1996). However, engraftment has
not been possible in other hereditary disorders, such as hemo-
globinopathies or storage diseases, likely because of immune
intolerance and competition by the host bone marrow environ-
ment (Flake and Zanjani, 1999). The limitations and risks as-
sociated with immunological barriers in acceptance of allo-
geneic grafts might be circumvented by gene therapy with
autologous genetically corrected CB cells transplanted in utero
(Zanjani and Anderson, 1999).
As a result of the transition of the hematopoietic site from
fetal liver to bone marrow during hematologic ontogeny (Tavas-
soli, 1991), stem cells are present in the fetal circulation dur-
ing the second and third trimester of pregnancy. The content of
hematopoietic progenitors in CB is higher during fetal life than
at birth (Clapp et al., 1989; Jones et al., 1994; Thialganathan
et al., 1994; Migliaccio et al., 1996; Shields and Andrews, 1998;
Surbek et al., 1998) and, furthermore, preterm CB is rich in im-
mature progenitors, defined phenotypically as CD341CD382
cells and functionally as long-term culture-initiating cells (LTC-
ICs) (Wyrsch et al., 1999). However, the total number of avail-
able fetal cells is low, limited by the volume of CB that can be
retrieved by fetal blood sampling. If the number of genetically
corrected transplanted cells is insufficient, they may be unable
to compete with and eventually replace the defective host
hematopoiesis. Experience in transplantation of stem cells from
bone marrow or “mobilized” peripheral blood has shown that
escalation of the stem cell dose can facilitate and accelerate en-
graftment (Sykes et al., 1997; Aversa et al., 1998; Reisner and
Martelli, 1999). To obtain adequate numbers of cells, expan-
sion of pluripotent hematopoietic progenitors in vitro might
prove clinically useful, and suitable culture conditions have
been particularly well described for CB cells (Broxmeyer et al.,
1992; Moore and Hoskins, 1994; Piacibello et al., 1997). We
have shown also that fetal CB progenitors can be extensively
expanded ex vivo (Wyrsch et al., 1999).
The goal of this work was to establish conditions for gene
delivery to immature fetal CB progenitors, using lentiviral vec-
tors for transfer of the green fluorescent protein (GFP) gene.
We show that transduction of human CB progenitors from the
second and early third trimester of pregnancy is as efficient as
that of term CB, and that extensive amplification of transduced
fetal CB cells with sustained transgene expression is possible.
These findings may prove useful for developing protocols for
autologous gene therapy of genetic diseases amenable to pre-
natal stem cell transplantation.
MATERIALS AND METHODS
Study population
Samples from term healthy newborns (n 5 4; weeks $35)
were collected after uneventful vaginal births or cesarean sec-
tions. Fetal CB included samples from the second (n 5 3; weeks
24–28) and early third (n 5 6; weeks 31–34) trimester of preg-
nancy, collected after abortions or preterm labor. Exclusion cri-
teria included clinically overt chorioamnionitis and preeclamp-
sia. There was no evidence of hematopoietic abnormalities in
the fetuses. Informed consent was obtained from the mothers
prior to delivery, and the investigations were approved by the
Ethics Committee of University Hospital Basel (Basel, Switzer-
land).
Cord blood cells
CB collection was performed according to Swisscord Com-
mission standard procedure. Shortly after delivery, the umbili-
cal cord was double clamped and dissected. CB was harvested
aseptically by umbilical vein puncture, and up to 10 ml was
collected in heparin-containing tubes. The delay between col-
lection and sample processing did not exceed 12 hr. CB
mononuclear cells were isolated by centrifugation on
Histopaque (d , 1.077 g/ml; Sigma, St. Louis, MO), and cryo-
preserved in liquid nitrogen in Iscove’s modified Dulbecco’s
medium (IMDM) containing 20% fetal calf serum (FCS; both
from GIBCO, Gaithersburg, MD) and 10% dimethyl sulfoxide
(DMSO; Sigma). On thawing, cells were left overnight in
IMDM–25% FCS containing DNase (100 IU/ml; Sigma) at 4°C.
CD341 cells were isolated with superparamagnetic MACS
(magnetic cell sorting) microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer instruc-
tions. The purity of the CD341 cell population ranged from 85
to 95%.
Growth factors
The following recombinant human growth factors were used:
PEGylated megakaryocyte growth and development factor
(MGDF; Amgen, Thousand Oaks, CA), Flt-3 ligand (FL; Im-
munex, Seattle, WA), stem cell factor (SCF; Amgen), inter-
leukin 3 (IL-3), IL-6, granulocyte-macrophage colony-stimu-
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lating factor (GM-CSF; all from Novartis, Basel, Switzerland),
granulocyte colony-stimulating factor (G-CSF; Rhône-Poulenc,
Antony, France), and erythropoietin (Epo; Boehringer Mann-
heim, Mannheim, Germany). Growth factors were used at a con-
centration of 100 ng/ml, except for MGDF at 50 ng/ml, IL-3
and IL-6 at 20 ng/ml, and Epo at 36 U/ml.
Transduction of CD341 progenitors with 
lentiviral vectors
Vesicular stomatitis virus glycoprotein (VSV-G)-pseudo-
typed lentiviral vectors were produced by cotransfection of hu-
man 293T cells with a packaging construct PCWT, a plasmid
(pMD.G) encoding protein G of VSV, and a transfer vector con-
taining the enhanced green fluorescent protein (GFP) gene un-
der the control of the phosphoglycerate kinase (PGK) promoter,
as described previously (Costello et al., 2000). Control vector,
lacking the VSV-G envelope, was generated by omitting the
pMD.G plasmid from transfections (Denv). Viral supernatants
were concentrated by ultracentrifugation and titers were deter-
mined on HeLa cells. Vector stocks with titers of 2–5 3 107
IU/ml were used. Vector supernatants were tested for the pres-
ence of replication-competent HIV, as described (Costello et
al., 2000). No replication-competent virus was detected. To in-
duce cell cycling prior to transduction, purified CD341 cells
were prestimulated for 3 days with IL-3, IL-6, SCF, and FL.
For transduction, 105 prestimulated or nonprestimulated CD341
cells were resuspended in 50 ml of IMDM with protamine sul-
fate (5 mg/ml; Sigma) in V-bottom tubes coated with fibronectin
fragment CH296 (Retronectin, 20 mg/cm2; TaKaRa, Shiga,
Japan) or bovine serum albumin (BSA; Behring, Marburg, Ger-
many). Lentivirus-containing supernatant was added (multi-
plicity of infection [MOI] of 15) and cells were centrifuged at
3000 rpm for 3 hr (spinoculation). Cells were then resuspended
in 1 ml of IMDM containing 20% FCS, and incubated for 24
hr at 37°C. In samples prestimulated with IL-3, IL-6, SCF, and
FL the same growth factors were present during transduction.
Cells were washed twice with IMDM supplemented with 2%
FCS. Transduction was repeated by spinoculation with a fresh
aliquot of lentiviral supernatant, and incubation for another 24
hr. For cell cycle analysis (see below), transduction was car-
ried out for 48 hr under the conditions described above, in the
presence of IL-3, IL-6, SCF, and FL, using nonprestimulated
CD341 cells.
Cell culture assays
After the 48-hr transduction period, cells were used to initi-
ate the following cultures.
Colony-forming unit assay. Aliquots of transduced cells from
term and fetal CB samples were plated into 1% methylcellu-
lose cultures supplemented with Epo, SCF, IL-3, G-CSF, and
GM-CSF (Wodnar-Filipowicz et al., 1992). Hematopoietic
colonies were counted after 14 days of culture and GFP-ex-
pressing colonies were identified with a fluorescence micro-
scope (Zeiss, Thornwood, NY).
Long-term culture-initiating cell assay. Determination of
LTC-ICs was performed as described (Sutherland et al., 1990).
The murine fibroblast cell line M210B4 (American Type Cul-
ture Collection, Manassas, VA) was used as a feeder layer af-
ter irradiation with 80 Gy and readherence in 96-well plates
overnight. Aliquots of transduced cells were seeded in quadru-
plicate wells over the feeders in 200 ml of IMDM containing
12.5% horse serum, 12.5% FCS, 0.016 mM folic acid, 0.16 mM
i-inositol (all from GIBCO), and 1026 M hydrocortisone
(Sigma). Cultures were maintained at 33°C for 5 weeks with
weekly half-medium changes. At the end of the culture period,
nonadherent cells were combined with the corresponding
trypsinized adherent cells, washed, and assayed in secondary
methylcellulose cultures for CFUs and GFP expression.
Amplification of transduced progenitors
Long-term liquid cultures were carried out as described
(Piacibello et al., 1997). After the 48-hr transduction period,
5000–20,000 transduced cells were seeded into 1 ml of LT
medium (IMDM containing 10% FCS, iron-saturated human
transferrin [380 mg/ml], 1% BSA), and supplemented with
MGDF and FL. Half-medium changes were performed weekly.
At weeks 1, 3, 6, and 10, harvested cells were counted and an-
alyzed by flow cytometry (fluorescence-activated cell sorting,
FACS) for GFP and CD34 expression, and aliquots were plated
into secondary methylcellulose cultures to determine CFUs. In
addition, at week 10, cells were seeded over M210B4 feeder
layers, and LTC-ICs and GFP expression were determined.
FACS analysis of GFP expression in CD341 cells
After the 48-hr transduction period, cells were maintained
for 3 days in LT medium containing IL-3, IL-6, SCF, and FL.
FACS analysis was performed on day 3 after transduction, thus
avoiding GFP expression background due to pseudotransduc-
tion. Staining was for 30 min with anti-CD34–phycoerythrin
(PE) (HPCA-2; Becton Dickinson, San Jose, CA) or the corre-
sponding isotype control antibodies at concentrations recom-
mended by the manufacturer, in FACS buffer containing phos-
phate-buffered saline (PBS), 0.5% BSA, and 0.02% sodium
azide. Dead cells were stained with propidium iodide (PI) for
10 min at 4°C. Cells were then washed, fixed for 10 minutes
with 2% paraformaldehyde (Sigma), and resuspended in FACS
buffer. FACS analysis for CD341 cells and the corresponding
GFP expression was performed on a FACS Calibur (Becton
Dickinson) acquiring no less than 10,000 events. Gates were
set according to forward and side scatter, and PI-positive cells
were excluded. Analysis was performed with CellQuest soft-
ware (Becton Dickinson).
Cell cycle analysis
Analysis was performed as described (Jordan et al., 1996)
with minor modifications. Freshly isolated or transduced cells
were resuspended in 1 ml of FACS buffer containing 0.4%
paraformaldehyde. After 30 min at 4°C, 1 ml of FACS buffer
with 0.2% Triton X-100 (Sigma) was added, and cells were per-
meabilized overnight at 4°C, washed twice in FACS buffer, and
stained with anti-Ki67–PE (Dako, Glostrup, Denmark) or an
isotype control antibody (IgG1–PE) for 60 min at 4°C. After
washing, cells were resuspended in FACS buffer containing 7-
aminoactinomycin D (7-AAD, 5 mg/ml; Sigma) and incubated
for 3 hr on ice. Whenever possible, 20,000 events were acquired
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on a FACSCalibur, using channels FL-1 for GFP, FL-2 for
Ki67–PE, and FL-3 for 7-AAD. Analysis was performed with
CellQuest software.
Detection of the GFP gene
Single CFUs and LTC-IC-derived colonies were plucked
from culture dishes with a micropipette tip and incubated for 1
hr at room temperature in 1 ml PBS. Cells were pelleted and
lysed for 1 hr at 56°C in 20 ml of cell lysis buffer (50 mM KCl,
10 mM Tris-HCl [pH 8.3], 1.5 mM MgCl2, gelatin [0.1 mg/ml],
0.45% Nonidet P-40, and 0.45% Tween 20) supplemented with
3 ml of proteinase K (10 mg/ml; Sigma). Samples were heated
at 95°C for 10 min at 2 ml of the lysate was used for poly-
merase chain reaction (PCR) amplification of a 304-bp frag-
ment of the GFP gene, using the sense primer 59-GCCA-
CAAGTTCAGCGTGTCC-3 9, the antisense primer 39-AGCT-
CGATGCGGTTCACCAG-5 9, and AmpliTaq DNA poly-
merase (Perkin-Elmer, Branchburg, NJ). The PCR was carried
out with 40 cycles of denaturation at 95°C for 1 min, anneal-
ing at 62°C for 1 min, and extension at 72°C for 1 min. A 438-
bp fragment of human b-actin was amplified to confirm the
presence of DNA and a control reaction containing water was
performed in each experiment. PCR products were separated
on 1.2% agarose gels stained with ethidium bromide, and bands
were visualized with a Gel Doc 2000 (Bio-Rad, Hercules, CA).
Statistical analysis
The transduction efficiency of fetal and term CB cells was
compared by means of the Student unpaired t test, using
StatView software (Abacus, Berkeley, CA).
RESULTS
Transduction efficiency of CD341 fetal CB cells by
lentiviral vectors
Our first goal was to optimize conditions for GFP gene trans-
fer by lentiviral vectors to CD341 progenitors isolated from fe-
tal CB. We tested various gene transfer protocols and invesi-
gated the need for cytokine-induced cell cycling. Preliminary
experiments revealed that the highest efficiency of GFP gene
transfer, as analyzed by FACS on day 3 after transduction, was
obtained when cells were exposed to the virus twice at 24-hr
intervals and transduced by the spinoculation method in the
presence of protamine sulfate; the use of a fibronectin fragment
brought no improvement (data not shown). Prestimulation with
IL-3, IL-6, SCF, and FL for 3 days prior to exposure to the
lentiviral vector significantly increased the transduction effi-
ciency (Table 1, Fig. 1). Using this combination of growth fac-
tors, the frequency of GFP-expressing fetal CD341 cells was
42 6 9% compared with 16 6 2% of cells transduced without
cytokine pretreatment, and, accordingly, the total number of
GFP1CD341 cells was about 4-fold higher. The transduction
efficiency of fetal cells was on average higher than that of
neonatal CB cells from term deliveries, both with and without
cytokine prestimulation (Table 1). These results demonstrate
that a transgene can be introduced and expressed in fetal CB
using lentiviral vectors.
We analyzed the cell cycle status of fetal CB progenitors,
and the efficiency of transduction with lentiviral vectors rela-
tive to the cell cycle phases. The distribution of CD341 cells
in the subcompartments of the cell cycle was defined by FACS
analysis of DNA by 7-AAD staining plotted against expression
of the nuclear antigen Ki67 expressed by cycling but not dor-
mant G0 cells (Jordan et al., 1996). Freshly isolated fetal CD341
cells were almost exclusively in G0/G1 phases: 71.5 6 3.4% of
G0-phase cells and 22.4 6 3.9% of G1-phase cells were found
in CB cells from weeks 24 to 31 of pregnancy, similar to the
proportions seen with term CB cells (Fig. 2A). When CD341
cells were exposed to the lentiviral supernatant on two consec-
utive days in the presence of IL-3, IL-6, SCF, and FL, the vast
majority of G0 cells progressed to G1 and S/G2/M phases, while
a small cell population remained quiescent (Fig. 2B). The num-
ber of cells in S/G2/M phases was reproducibly higher in fetal
than in term CB, indicating that fetal cells responded more read-
ily to cytokine stimulation. The higher proportion of cycling
cells may account for the better transduction efficiency in fetal
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TABLE 1. EFFICIENCY OF TRANSDUCTION OF FETAL AND TERM CB CD341
PROGENITOR CELLS, AND OF CFU- AND LTC-IC-DERIVED COLONIES
Pre PCR1/ PCR1/GFP2
stimulationc % Totald % Totald GFP2 CFUse % Totald LTC-ICs e
Fetal CBf 1 42 6 9** 49,772 6 168 23 6 4 4,061 6 282 0/10 11 6 1 226 6 65 1/10
2 16 6 2** 11,232 6 560 10 6 1 1,184 6 235 0/90 09 6 4 120 6 54 2/90
Term CB 1 24 6 3** 32,032 6 200 23 6 1 4,039 6 479 0/90 11 6 4 185 6 45 0/90
2 5 6 2** 4,792 6 112 9 6 4 1,010 6 650 0/10 16 6 5 138 6 32 4/10
aThe frequency of GFP1CD341 cells was analyzed by FACS 3 days after the 48-hr transduction period. Significance of the
difference between fetal and term CB samples: *p , 0.04; **p , 0.01.
bCFU and LTC-IC cultures were initiated immediately after the 48-hr transduction period. GFP1 colonies were detected by
fluorescence microscopy.
cCB CD341 cells were transduced either after prestimulation with IL-3, IL-6, SCF, and FL for 3 days (1) or without pre-
stimulation (2).
dCalculated per 1 3 105 CD341 cells subjected to prestimulation, if any, and transduction.
ePCR for the detection of the GFP gene was performed with DNA isolated from single CFU- or LTC-IC-derived colonies
scored GFP2 by fluorescence microscopy.
fFetal CB cells were from weeks 26, 31, 32, and 34 of gestation.
GFP1CD341 cellsa GFP1 CFUsb GFP1 LTC-ICsb
than in term CD341 cells observed after 3 days of culture (Table
1). GFP expression was found in all phases of the cell cycle:
7.1% of G0, 12.1% of G1, and 16.2% of S/G2/M fetal CB cells
were GFP1 (Fig. 2B). GFP expression in cells in the G0 phase
suggests that resting progenitors were transduced by lentiviral
vectors. The proportion of GFP-expressing cells was higher in
fetal than in term CB samples in every cell cycle phase.
Transduction of fetal CB-derived CFUs and LTC-ICs
by lentiviral vectors
To determine the ability of lentiviral vectors to transduce
colony-forming CB progenitors, CD341 cells were exposed to
the vector, as described above, and GFP expression was ana-
lyzed in colonies derived from commited CFU and primitive
LTC-IC precursors. The transduction procedure did not impair
colony growth, in comparison with nontransduced cells, in ei-
ther type of culture, and no GFP expression was detected in
cultures initiated with mock-transduced (Denv) cells (not
shown). The frequency of GFP1 colonies formed by fetal and
neonatal progenitors, as determined by fluorescence mi-
croscopy, was similar despite the superior transduction effi-
ciency of fetal cells seen at an earlier time point with flow cy-
tometry. On average, 23% of fetal CFU-derived colonies
expressed GFP when transduction was preceded by 3 days of
prestimulation with IL-3, IL-6, SCF, and FL (Table 1). This
was about 2-fold higher than the frequency of GFP1 colonies
derived from nonprestimulated cells, and also the total number
of transduced colonies was higher, confirming the effect of cy-
tokines observed by FACS analysis of CD341 cells on day 3
after transduction. The average frequency of GFP-expressing
colonies scored in the LTC-IC assay was 11% (Table 1). This
frequency, and the total amount of transduced LTC-ICs, was
not markedly influenced by cytokine pretreatment, suggesting
that progenitors detected in the assay represent cells remaining
quiescent during transduction, in agreement with a significant
enrichment in LTC-ICs in the G0 compared with the G1 com-
partment (Gothot et al., 1998). Examples of GFP1 progeny of
LTC-IC precursors from fetal CB are shown in Fig. 3. Notably,
highly variable intensity of GFP expression was observed in
cells belonging to the same colony defined as GFP positive by
fluorescence microscopy, suggesting transgene silencing in
some transduced cells. To investigate further the possibility of
a “shutdown” of transgene expression during the culture period,
we used PCR to assess the presence of the GFP gene in DNA
from colonies scored as GFP negative by fluorescence mi-
croscopy. While none of the tested CFU-derived GFP-negative
colonies contained the GFP-specific sequences, these were de-
tected in 3 of 19 (16%) and 4 of 19 (21%) LTC-IC derived
colonies from fetal and neonatal CB, respectively (Table 1).
The presence of GFP sequences in the absence of GFP ex-
pression suggests that the frequency of transduced LTC-IC pre-
cursors was higher than estimated by fluorescence microscopy,
and that expression of integrated transgene was downregulated
during the prolonged culture period.
Expansion of GFP1 fetal CB progenitors transduced
by lentiviral vectors
We have previously shown that precursors from fetal CB can
be extensively expanded ex vivo in cultures containing MGDF
and FL (Wyrsch et al., 1999). To test the expansion capacity
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FIG. 1. GFP expression by fetal CB progenitor cells transduced with lentiviral vectors. CD341 cells from fetal (week 31) and
term CB were transduced either after prestimulation for 3 days with IL-3, IL-6, SCF, and FL (A), or without prestimulation (B),
as described in Materials and Methods, and GFP expression was analyzed by FACS (solid line). Cells transduced with a Denv
vector were used as a control (dotted line). The percentage of GFP1 cells is indicated.
of transduced CD341 cells, analogous long-term liquid cultures
were initiated after exposure to lentiviral vector. In agreement
with our earlier results, fetal and neonatal CB CD341 cells grew
with the same kinetics (not shown) and an amplification of
CD341 cells and CFUs of about 1000-fold was observed after
10 weeks (Fig. 4A). At this time point, the content of CD341
cells in liquid cultures was 4.1 6 2.0%, of which 2.9 6 1.4%
were CD341CD382 (not shown). Pretreatment with IL-3, IL-
6, SCF, and FL for 3 days prior to exposure to lentivirus had
no influence on the total output of the progenitors in long-term
cultures with MGDF and FL (Fig. 4A). However, this treatment
had a negative effect on long-term maintenance of GFP ex-
pression by both fetal and term CB cells (Fig. 4B). An initial
advantage of prestimulation with cytokines for the transduction
efficiency (see also Fig. 1 and Table 1) was observed only un-
til week 3, when about 45% of fetal CFUs were GFP1. There-
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FIG. 2. Relationship between cell cycle status and transduction efficiency of fetal CB progenitors. (A) Cell cycle analysis of
fetal and term CD341 cells. CD341 cells were stained with Ki67–PE and 7-AAD and analyzed as described in Materials and
Methods. Gates were set according to the staining with IgG1–PE. Examples of CB from weeks 24 and 31 of gestation, and from
a term pregnancy, are shown. The percentage of cells in the G0, G1, and S/G2/M phases of the cell cycle is indicated beneath
each dot plot. (B) Cell cycle status and efficiency of transduction with lentiviral vectors. Fetal (week 31) and term CD341 cells
were transduced for 48 hr (see Materials and Methods) and stained with Ki67-PE and 7-AAD as described above, and three-
color FACS analysis was performed. The percentage of cells in the G0, G1, and S/G2/M phases of the cell cycle and corre-
sponding GFP expression are indicated.
after, the content of GFP1 colonies declined rapidly to 1.7 6
1.0% by week 10. In contrast, an initially lower frequency of
GFP1 colonies in cultures generated from cells transduced
without cytokine pretreatment gradually increased and GFP ex-
pression was detected in 40.5 6 11.7% of CFUs present after
10 weeks of expansion. The maintenance of transgene expres-
sion in fetal cell cultures was similar to that of term CB pro-
genitors. Expression of GFP was multilineage, observed in both
myeloid and erythroid colonies formed by transduced fetal
clonogenic progenitors. In addition, after expansion over 10
weeks, we could also obtain differentiation of the transduced
progenitors to dendritic cells and natural killer cells under ap-
propriate culture conditions (not shown).
To confirm the maintenance of GFP1 cells during expan-
sion, and to evaluate the intensity of GFP expression in trans-
duced fetal cells, flow cytometry was used (Fig. 5). The GFP1
population was maintained in cultures not preexposed to growth
factors, whereas it was progressively lost in cultures of pre-
stimulated cells, in agreement with the outcome in clonogenic
GFP1 cells (see Fig. 4B). Interestingly, in both growth factor-
prestimulated and nonprestimulated cells, the intensity of GFP
fluorescence decreased as a function of time (Fig. 5A and B).
Reduction in signal intensity was evident at week 3, and the
fluorescence became dull by week 10, despite the presence of
a well-pronounced population of GFP1 cells in nonprestimu-
lated cultures (Fig. 5A). A similar decline in GFP fluorescence
intensity was also seen in cultures of term CB (not shown).
These results speak for a gradual downregulation of transgene
expression during the prolonged culture period, as suggested
before by detection of integrated GFP sequences in LTC-IC-
derived colonies without detectable transgene expression (see
Table 1).
To explore further the maintenance of GFP expression in
transduced progenitors, we analyzed LTC-ICs after 10 weeks
of expansion in cultures with MGDF and FL. Approximately
50,000 to 110,000 LTC-ICs derived from 105 fetal CB CD341
cells were measured (not shown), representing a 40- to 60-fold
amplification of LTC-ICs during expansion. However, none of
the analyzed colonies displayed GFP expression detectable by
fluorescence microscopy, consistent with a downregulation of
transgene expression during the prolonged culture period. This
was further confirmed by the presence of integrated GFP-spe-
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FIG. 3. GFP expression by LTC-IC-derived colonies from fetal CB progenitors, assessed by fluorescence microscopy. LTC-
IC cultures with transduced cells were initiated on M210B4 fibroblasts as described in Materials and Methods. After 5 weeks,
cells were plated into methylcellulose cultures, and the resulting colonies were assessed after 14 days with a fluorescence (A and
C) and an inverted light (B and D) microscope. Colonies derived from a granulocyte-macrophage (GM-CFU; A and B) and a
granulocyte-macrophage erythroid megakaryocyte (GEMM-CFU; C and D) precursor from fetal CB (week 32) are shown.
cific sequences found by PCR in DNA isolated from 7 of 20
(35%) and 4 of 10 (40%) fetal and neonatal CB LTC-IC-de-
rived colonies, respectively (Fig. 6). The frequency of
PCR1/GFP2 LTC-IC colonies was not influenced by growth
factor stimulation prior to transduction. The presence of the
GFP gene in colonies formed after 10 weeks of expansion and
the additional 7 weeks needed to enumerate LTC-ICs provide
evidence that the transgene had been initially transferred to im-
mature progenitors with a high potential for self-renewal. This
is in accordance with the results of cell cycle analysis that
demonstrated GFP expression in resting G0-phase cells.
DISCUSSION
Many genetic diseases of the lymphohematopoietic system
can now be diagnosed early in gestation and technologies of
noninvasive sampling and reliable molecular screening are be-
ing developed. Prenatal diagnosis is the basis for in utero gene
therapy with autologous genetically corrected hematopoietic
stem cells (Surbek et al., 1999). If sufficient cells could be col-
lected by cordocentesis during pregnancy, genetically modified
ex vivo and transplanted in utero, clinical manifestations of the
disease could be prevented before birth (Flake and Zanjani,
1999; Schneider and Coutelle, 1999; Zanjani and Anderson,
1999). We have demonstrated that fetal CB obtained from hu-
man fetuses in the second and early third trimester of pregnancy
is rich in hematopoietic precursors with high self-renewal ca-
pacity (Wyrsch et al., 1999). Here, we describe the use of a
lentivirus-based gene transfer vector for efficient transduction
of human CD341 progenitor cells from CB of early gestational
stages with the GFP marker gene.
The results demonstrated that 42 6 9% of CD341 from CB
at weeks 24–34 of pregnancy were transduced by the lentiviral
vector. This efficiency was higher than that of CB cells from
full-term pregnancies, perhaps as a result of the higher prolif-
erative capacity of fetal cells, also reflected in the formation of
larger colonies and higher replating potential, compared with
term CB cells (Migliaccio et al., 1996; Shields and Andrews,
1998). Analysis of the dependence of transgene expression on
cell cycle activity showed that freshly isolated fetal CD341 cells
were largely residing in G0 phase and, on cytokine stimulation,
rapidly entered G1 phase. GFP expression was found in a small
proportion of residual dormant G0-phase cells, and the bulk ex-
pression was evenly distributed among cells that progressed to
G1 phase and actively dividing S/G2/M-phase cells. These find-
ings are in accordance with the properties of lentiviral vectors,
which have been shown to transduce both quiescent and pro-
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FIG. 4. Long-term expansion of fetal CB progenitors transduced with lentiviral vectors. CD341 cells, either prestimulated for
3 days with IL-3, IL-6, SCF, and FL or nonprestimulated, as indicated, were transduced with lentiviral vectors. Subsequently,
cells were cultured in the presence of MGDF and FL for 10 weeks. Aliquots of cells were analyzed by FACS for CD34 and GFP
expression and assayed for CFUs at weeks 0, 1, 3, 6, and 10. (A) Amplification of CD341 cells (solid line) and CFUs (dotted
line) in cultures with MGDF and FL. The total output of CD341 cells and CFUs 1 SEM per culture initiated with 5000 cells is
shown. (B) GFP expression by CFUs derived from fetal and term CB progenitors cultured in the presence of MGDF and FL.
Shown is the percentage of GFP1 CFUs derived from cells transduced after 3 days of prestimulation (open columns) or without
prestimulation (solid columns). The significance of the differences between prestimulated and nonprestimulated cells was *p ,
0.04 in favor of prestimulated cells at week 0, and **p , 0.01 in favor of nonprestimulated cells at week 10, for both fetal and
term CB.
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liferating hematopoietic progenitors (Uchida et al., 1998; Case
et al, 1999), however, at greater efficiency once the cells exit
G0 and enter G1 phase (Sutton et al., 1999). Transduction rates
were higher after preculture with IL-3, IL-6, SCF, and FL, as
also previously reported for term CB progenitors (Evans et al.,
1999; Sutton et al., 1999). Likewise, we have previously re-
ported that activation of resting T cells with CD3 and CD28
antibodies, resulting in cell cycling prior to transduction with
lentiviral vectors, increased gene transfer efficiency (Costello
et al., 2000). Cell stimulation may have a positive effect on
transduction by raising pools of nuclear deoxynucleoside
triphosphates for reverse transcription of viral RNA (Sutton et
al., 1999). When applying identical transduction conditions to
fetal and term CD341 cells, the number of fetal cells remain-
ing in G0 phase was reproducibly lower, indicating that they re-
sponded more readily to cytokine stimulation. This effect may
contribute to the initially higher transduction efficiency of fe-
tal CB cells. In colony assays, GFP expression was observed
in about 23% of CFU progeny and 11% of more primitive LTC-
IC-derived colonies and was equal for both fetal and term CB
cells.
Interestingly, long-term maintenance of transgene expression
was clearly superior when freshly isolated CD341 cells were
subjected to transduction directly, omitting the cytokine pre-
stimulation step. While efficiency of GFP gene transfer was ini-
tially increased 2- to 3-fold by preculture with IL-3, IL-6, SCF,
and FL, induction of cell cycling prior to transduction had a
negative effect on GFP expression by cells maintained in long-
term cultures. Only 1.7 6 1.0% of GFP-expressing cells was
present after 10 weeks of culture in MGDF and FL. In contrast,
when the cytokine stimulation step prior to transduction was
omitted, the proportion of fetal GFP1 CFUs increased gradu-
ally to 40.5 6 11.7%. A proportional increase in the content of
transgene-expressing cells has also been reported on culturing
of cell cycle-arrested fibroblasts transduced with lentiviral vec-
tors (Naldini et al., 1996). In cultures of hematopoietic cells,
an increase in transgene expression may reflect changes in the
cell population during long-term expansion; indeed, an in-
creasing contribution by more primitive CD341CD382 cells
under these culture conditions was described (Piacibello et al.,
1997).
In long-term cultures, GFP expression was subject to grad-
ual downregulation, as evidenced by a progressive loss of flu-
orescence intensity by a GFP1 cell population, irrespective of
the conditions of transduction and further propagation of cells.
In agreement, the frequency of colonies containing GFP-spe-
cific sequences integrated into cellular DNA but lacking GFP
expression increased over time. After 10 weeks of liquid cul-
ture with MDGF and FL, and a further 7 weeks on stroma sup-
port, 35% of transduced LTC-ICs in fetal CB contained the
transgene, but expression of GFP was undetectable by fluores-
cence microscopy. It is conceivable that loss of GFP expres-
sion without the loss of the expression construct was due to
transgene silencing during the prolonged culture. Gradual
downregulation of expression of a transferred gene in the case
of retroviral delivery vectors is a phenomenon recognized as a
threat to the efficacy of gene therapy (Bestor, 2000; Trono,
2000). Although the precise mechanism accounting for gene
shutoff in hematopoietic cells is not understood, de novo methy-
lation is likely to play a role in the transcriptional silencing of
transduced genes (Bestor, 2000). Activity of CpG methyltrans-
ferases is upregulated in response to nitric oxide, the produc-
tion of which is known to increase in response to hematopoi-
etic growth factors (Punjabi et al., 1992; Hmadcha et al., 1999).
Silencing may particularly strongly affect transgenes under the
control of CpG-rich promoters, such as the human PGK pro-
moter used in this study (Pfeifer et al., 1990). Therefore, choice
of promoters (Fahlmann et al., 1999) or inclusion of insulator
regions preventing spread of methylation (Pikaart et al., 1998;
Rivella et al., 2000) is an important consideration in designing
vectors for gene transfer.
Clinical experience with in utero stem cell transplantation
showed that failure of engraftment was not only due to immune-
mediated rejection of allogeneic grafts, but also to a lack of se-
lective growth advantage for normal relative to defective cells
in the bone marrow of the recipient (Flake and Zanjani, 1999).
This latter obstacle is also likely to restrain repopulation with
autologous genetically corrected cells. Because myeloablative
treatment to create space in the bone marrow is not feasible in
the fetus, an alternative is to increase the number of transplanted
cells to enhance engraftment. This work demonstrated that an
extensive amplification of transduced fetal CD341 clonogenic
cells capable of giving rise to multiple hematopoietic lineages
expressing GFP is possible. Although the functional character-
ization of fetal cells in all available in vitro assays, including
current results on susceptibility to lentiviral transduction, re-
vealed a growth behavior equal to that of progenitors from term
CB, the repopulation ability of lentiviral vector-transduced and
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FIG. 6. PCR analysis of GFP gene integration in DNA of LTC-IC-derived colonies from fetal and term progenitors after 10
weeks of culture in MGDF and FL. Colonies from cultures of cells transduced without prestimulation and scored negative for
GFP expression with the fluorescence microscope were plucked from the culture dishes. Cells were lysed, and aliquots were sub-
jected to PCR amplification of a fragment of the GFP gene (304 bp) and of the human b-actin gene (438 bp). Results from 10
fetal and term CB-derived colonies are shown.
expanded human fetal CB needs to be confirmed in vivo in the
NOD/SCID mouse. Importantly, under conditions analogous to
those used here for expansion of transduced fetal CB progeni-
tors, efficient engraftment has been reported with term CB cells
expanded for up to 10 weeks in long-term cultures containing
MGDF and FL (Piacibello et al., 1999). Also, other growth fac-
tor combinations allowed maintenance or moderate expansion
of repopulating cells over shorter time periods (Conneally et
al., 1997; Dorrell et al., 2000; Ueda et al., 2000).
Lentiviral vectors are capable of efficient and stable trans-
duction of primitive progenitors from bone marrow, “mobilized”
peripheral blood, and CB (Sutton et al., 1998, 1999; Uchida et
al., 1998; Case et al., 1999; Evans et al., 1999; Miyoshi et al.,
1999). Direct comparison between the transduction efficiency of
lentivirus- and oncoretrovirus-derived vectors provided evidence
that lentiviral vectors are superior for gene delivery to primitive
quiescent hematopoietic cells (Uchida et al., 1998; Case et al.,
1999; Evans et al., 1999). Since in lentiviral vector transduction,
the transgene can integrate without growth factor stimulation, de-
pletion of marrow-repopulating cells can be minimized and stem
cells capable of long-term expression of the therapeutic gene can
be preserved. The important issue of optimizing the biological
safety of this system prior to clinical application has led to the
design of vectors that exclude the possibility of recombination
of infective viral particles (Zufferey et al., 1997, 1998; Buch-
schacher and Wong-Staal, 2000). We have found that lentiviral
vectors, in which most accessory HIV genes have been deleted
and self-inactivating mutations have been introduced (a gift of
D. Trono, Geneva University, Switzerland), thus being designed
for a high degree of biosafety (Zufferey et al., 1998), can trans-
duce fetal CB progenitors with the same efficiency as the vec-
tors in this study (A. Luther-Wyrsch, unpublished results).
While postnatal gene therapy is already possible for some
diseases (Kohn et al., 1998; Cavazzana-Calvo et al., 1999), ther-
apy with autologous CB stem cells harvested during pregnancy
and genetically modified ex vivo has not yet been attempted.
Although fetal gene therapy first needs to be established ex-
perimentally in animal models, medical and ethical aspects of
this novel treatment option in humans are currently under con-
sideration (Zanjani and Anderson, 1999). Risks and benefits to
the mother and child will also determine the choice of optimal
time for gene therapy in utero. One study has documented cir-
culating progenitor cells already in the first trimester of non-
continuing pregnancies (Campagnoli et al., 2000), but early fe-
tal CB sampling is inefficient and may pose a significant risk
to the fetus (Orlandi et al., 1990; Wyrsch et al., 1999). Since
autologous transplantations do not depend on the permissive
environment of the immunologically immature fetus, gene ther-
apy later in pregnancy seems more appropriate. The results of
our experiments show that CB progenitors obtained in the sec-
ond and early third trimester can be targeted for gene transfer
by lentiviral vectors and may, therefore, prove useful for au-
tologous gene therapy of genetic diseases amenable to prenatal
stem cell transplantation.
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